Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q2 FY16 Earnings Presentation
22 slides from Alembic Pharmaceuticals's earnings presentation, October 2015
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation October 2015 www.alembic-india.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: About Alembic
About Alembic Established in 1907 at Vadodara Demerger of pharma business from Alembic Ltd. – Alembic Pharmaceuticals Ltd. formed in 2011 Investment in Algeria JV Three API manufacturing facilities approved by USFDA One solid dosage formulation facility approved by USFDA 18 Marketing div
Slide 4: Financial Highlights Q2 FY16
Financial Highlights Q2 FY16 Net Sales up 85% to Rs 10177 mn EBITDA margins at 37% at Rs 3760 mn Net Profit up 274% to Rs 2889 mn Total R&D spend is Rs 956 mn for the quarter which is 9.4% of net sales.
Slide 5: Business Highlights Q2 FY16 India Branded Formulations
Business Highlights Q2 FY16 India Branded Formulations (Rs. 2846 mn) Specialty Segment grew by 21% and Acute Segment de-grew by 9%. Althrocin price cut also contributed to acute segment degrowth Strengthening the share of specialty therapies in the overall revenue basket. Within specialty Cardio
Slide 6: Business Highlights Q2 FY16 International Generics
Business Highlights Q2 FY16 International Generics (Rs. 5593 mn) Business grew by 342% in the quarter Successful Launch of Aripiprazole Generic on Day one 1 product launch in USA USA front end launched 2 ANDA approvals were received during the quarter, taking cumulative approvals at 44 inc
Slide 7: Business Highlights Q2 FY16 API Business
Business Highlights Q2 FY16 API Business (Rs. 1372 mn) Business grew by 43% in the quarter 2 DMF applications were filed during the quarter, taking cumulative DMF filings at 75
Slide 8: R&D Update
R&D Update 9.8% 7.0% 6.7% 4.8% 5.1% 1,581 1,394 1,308 702 772 In INR mn FY12 FY13 FY14 FY15 H1 FY16 Total R&D spend is Rs 1581 mn for the H1 FY16 which is 9.8% of net sales. Highly talented pool of 470 research scientists
Slide 9: Strong domestic market presence
Strong domestic market presence India Branded Formulation Business - Key Highlights 1.76% market share (Ranked 19th) in Indian formulations market as per IMS MAT data Sustained dominance in anti-infective, analgesics, cough and cold segments Robust growth in Cardiology, Diabetes, Gastrology, G
Slide 10: Key Therapies & Brands
Key Therapies & Brands Therapeutic Segment-wise Break-up (Q2FY16) • Launched 12 product SKUs in the domestic market in Q2FY16. % of total domestic formulation revenue Brand Name Therapeutic Area Ranking Anti Infectives 2 21 Azithral Anti-infective 34 4 Gastrology 6 Cardiology Althrocin Anti-infectiv
Slide 11: Continued shift towards Specialty therapies
Continued shift towards Specialty therapies Therapy Dominance % of Domestic Formulations 43 38 51 46 58 54 57 62 49 54 42 46 FY11 FY12 FY13 FY14 FY15 HYFY16 Specialty Acute
Slide 12: Therapy-wise Performance Q2 FY16
Therapy-wise Performance Q2 FY16 SEP QTR 2015 SEP QTR 2014 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 16 2.01 39 34 12 1.68 25 30 Anti Diabetic 21 1.54 34 31
Slide 13: Fast emerging player in International Generics
Fast emerging player in International Generics International Generics Business - Key Highlights Launched own front-end marketing in the USA All Facilities approved for supply to regulated markets such as the US, Europe, Australia and Brazil Partnership with leading generic players in the US, E
Slide 14: Financial Snapshot
Financial Snapshot
Slide 15: Financial Highlights
Financial Highlights Particulars (INR mn) Q2 FY16 Q2 FY15 H1 FY16 H1 FY15 %Growth Formulations Revenue India Branded 2846 2755 5474 4988 10% Generics 251 322 537 574 (-)7% International Branded 116 187 201 418 (-)52% Generics 5592 1264 7301 2435 200% API Revenue 1372 960 2568 2034 26% Total Revenue
Slide 16: Financial Ratios
Financial Ratios Various Ratios H1 FY 16 H1 FY 15 FY 15 EBIDTA Margin 30.03% 19.56% 19.69% Gross Margin 72.23% 64.80% 65.29% ROCE 62.88% 34.22% 30.59% RONW 57.93% 34.87% 31.98% EPS 19.01 7.53 15.01 Book Value per share 65.63 43.18 46.93 Debt Equity Ratio 0.13 0.28 0.30 EBITDA / Debt Ratio 0.16 0.56
Slide 17: Revenue Trend
Revenue Trend CAGR 20677 18684 9808 8506 15260 7484 In INR mn 5185 4684 2358 3506 3389 3665 FY13 FY14 FY15 API International Generics India Branded Formulations Total Revenue
Slide 18: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 14 Promoter & Promoter group 12 FI/FII/MF 74 Public Market capitalization INR 129 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders >50 K Free float market INR 33 bn capitalization
Slide 19: Strategy going forward
Strategy going forward Continue to focus on complex products. Expect to launch 7-9 products every year for the next three years in the US markets Aggressive investments in R&D and F&D activities to build robust pipeline of products for regulated markets More products through our USA front end.
Slide 20: Conference call details
Conference call details Date : Tuesday, October 27, 2015 Time : 05.00 pm IST India - Primary Number +91 22 39381028 India - Secondary Number +91 22 67468328 USA 1 866 746 2133 UK 0 808 101 1573 Singapore Toll Free No. 800 101 2045 Hong Kong Toll Free No. 800 964 448
Slide 21: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharm
Slide 22: Thank You
Thank You
Alembic Pharmaceuticals — Q2 FY16 Earnings Presentation on 6ix